Trial Profile

A Phase 1, Open-Label Study to Evaluate the Effect of Itraconazole and Mefenamic Acid on the Single-Dose Pharmacokinetic Profile of Soticlestat in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Soticlestat (Primary) ; Itraconazole; Mefenamic acid
Indications Complex regional pain syndromes; Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Myoclonic epilepsies; Tuberous sclerosis
Focus Pharmacokinetics
Sponsors Takeda

Most Recent Events

06 Dec 2022 Results assessing the effects of itraconazole (strong CYP3A inhibitor), mefenamic acid (MA; strong UGT1A9 inhibitor) and rifampicin (strong CYP3A inducer) on the pharmacokinetics (PK) of soticlestat, presented at the 76th Annual Meeting of the American Epilepsy Society.
01 Dec 2021 Status changed from active, no longer recruiting to completed.
10 Nov 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com